Repare Therapeutics, Inc. (RPTX)

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation

Ask a question about Repare Therapeutics, Inc. (RPTX)

Company Performance

Current Price

as of Oct 16, 2024

$3.42

P/E Ratio

N/A

Market Cap

$145.16M

Description

Repare Therapeutics, Inc. engages in the research, development, and commercialization of precision oncology drugs targeting specific vulnerabilities of tumors in genetically defined patient populations. The company was founded on September 6, 2016 and is headquartered in Saint-Laurent, Canada.

Metrics

Overview

HQSaint-Laurent, QC
SectorHealth Technology
IndustryPharmaceuticals: Major
TickerRPTX
Price$3.42+1.79%

Trading Information

Market Cap$145.16M
Float67.68%
Average Daily Volume (1m)129,129
Average Daily Volume (3m)108,671
EPS-$1.62

Company

Revenue$68.68M
Rev Growth (1yr)-96.45%
Net Income-$34.77M
Gross Margin54.52%
EBITDA Margin-3,408.29%
EBITDA-$36.57M

EV-$65.88M
EV/Revenue-0.96
P/EN/A
P/S2.11
P/B0.71

Documents

Factset

Factset Business Description

Factset Street Account

Repare Therapeutics unveils two programs expected to enter clinical trials in 2024: RP-1664, an Oral PLK4 Inhibitor, and RP-3467, an Oral Polθ Inhibitor ($4.08, 0.00) (2023-11-15T12:08:45Z)

Repare Therapeutics to host conference call and webcast to discuss initial Phase 1 MYTHIC Modules 1 and 2 clinical data presented at 35th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics ($11.79, 0.00) (2023-10-03T11:06:38Z)

Repare Therapeutics reports Q3 EPS ($0.45) vs FactSet ($0.86) [8 est, ($1.05)-(0.67)] ($4.11, 0.00) (2023-11-09T12:06:44Z)

Repare Therapeutics reports positive initial data from Phase 1 MYTHIC Clinical Trial ($5.60, 0.00) (2023-10-13T13:48:39Z)

Repare Therapeutics holder Biotechnology Value Fund, L.P. switches filing type from 13G (passive) to 13D (active); discloses 21.6% stake vs prior 19.7% stake - 13D ($3.81, 0.00) (2023-11-03T21:40:12Z)